Thermo Fisher Scientific Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Thermo Fisher Scientific Inc (TMO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Thermo Fisher Scientific Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 46,336M vs 808,976M combined for tracked competitors (5.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.5% annualized vs trailing 12 months), vs accelerating (+5.2%) for its tracked peer group.
- Growth: Thermo Fisher Scientific Inc generated 10.5% revenue growth year over year in Q2 2026, vs 8.7% for its tracked competitors combined.
- Profitability: Its 14.5% net margin compares with 22.0% for the peer group.
- Scale: Thermo Fisher Scientific Inc ranks #1 of 21 companies by market capitalization in the Scientific & Technical Instruments industry, holding 38.3% of industry market cap.
- Peer revenue share: Thermo Fisher Scientific Inc accounted for 5.3% of combined revenue among its tracked peer group, up from 5.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.37M compares with $0.74M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TMO Sales vs. its Competitors, Q2 2026
Thermo Fisher Scientific Inc reported revenue growth of 10.49 % year on year in Q2 2026, above its competitors' combined revenue growth of 8.72 %.
With a net margin of 14.52 %, Thermo Fisher Scientific Inc reported lower profitability than its competitors (21.98 %).
Thermo Fisher Scientific Inc generated 5.34 % of the combined sales of its peer group, up from 5.26 % a year earlier.
Thermo Fisher Scientific Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Thermo Fisher Scientific Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Thermo Fisher Scientific Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (22) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Thermo Fisher Scientific Inc's competitor groups requires a Commercial License.
For context: the Scientific & Technical Instruments industry grew revenue 12.8% year over year, combined, vs 10.5% for Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc's share of combined industry revenue moved from 49.34% to 48.34%, a loss of 1.01 percentage points.
Thermo Fisher Scientific Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | Yes | Yes | No | Yes |
| Competitors combined (108) | ||||
| High-Confidence Competitors (28) | ||||
| Similar-Size Competitors (5) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TMO Stock Performance relative to its Competitors
TMO Stock Performance relative to High-Confidence Competitors
TMO Stock Performance relative to Similar-Size Competitors
TMO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | 10x Genomics Inc | 282.9% | Outperformed |
| 2 | Twist Bioscience Corporation | 282.9% | Outperformed |
| 3 | Ase Technology Holding Co Ltd | 282.9% | Outperformed |
| 4 | Skywater Technology Inc | 282.9% | Outperformed |
| 5 | Formfactor inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Thermo Fisher Scientific Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Thermo Fisher Scientific Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Thermo Fisher Scientific Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Thermo Fisher Scientific Inc | 251,760.60 | 46,336.00 |
| Taiwan Semiconductor Manufacturing Company Limited | 2,348,690.03 | 121,423.20 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Abbott Laboratories | 176,419.43 | 45,134.00 |
| Danaher Corporation | 160,858.71 | 25,107.00 |
| Intuitive Surgical Inc | 148,204.47 | 11,296.30 |
| SUBTOTAL | 5,207,294.43 | 1,583,212.18 |
Sign in to see all competitors of Thermo Fisher Scientific Inc .
Sources: Thermo Fisher Scientific Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Thermo Fisher Scientific Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Thermo Fisher Scientific Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Agilent Technologies inc | Named by the company | 85% |
| Guardant Health Inc | Named by the company | 85% |
| Medpace Holdings Inc | Named by the company | 85% |
| Atlantic International Corp | Named by the company | 85% |
| Cytek Biosciences Inc | Named by the company | 85% |
| Ingersoll Rand Inc | Named by the company | 85% |
| Quanterix Corporation | Named by the company | 85% |
| Twist Bioscience Corporation | Named by the company | 85% |
| Azenta Inc | Named by the company | 85% |
| Quidelortho Corp | Named by the company | 85% |
| Telesis Bio Inc | Named by the company | 85% |
| Auburn National Bancorporation Inc | Named by the company | 85% |
| Emergent Biosolutions Inc | Named by the company | 85% |
| 908 Devices inc | Named by the company | 85% |
| Singular Genomics Systems Inc | Named by the company | 85% |
| Sophia Genetics Sa | Named by the company | 85% |
| Volitionrx Limited | Named by the company | 85% |
| Caredx Inc | Named by the company | 85% |
| Iqvia Holdings Inc | Named by the company | 85% |
| Maxcyte inc | Named by the company | 85% |
| Quantum si Incorporated | Named by the company | 85% |
| Bio techne Corp | Named by the company | 85% |
| Accelerate Diagnostics Inc | Named by the company | 85% |
| Palisade Bio Inc | Named by the company | 85% |
| SQL | Named by the company | 85% |
| Waters Corporation | Named by the company | 85% |
| Nautilus Biotechnology Inc | Named by the company | 85% |
| Icon Plc | Named by the company | 85% |
| Mirion Technologies Inc | Named by the company | 85% |
| Bio rad Laboratories Inc | Named by the company | 85% |
| Us Nuclear Corp | Named by the company | 85% |
| Harvard Bioscience Inc | Named by the company | 85% |
| Veracyte Inc | Named by the company | 85% |
| Cue Health Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Thermo Fisher Scientific Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Thermo Fisher Scientific Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Johnson and Johnson | Oncology 29.26 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Danaher Corporation | Diagnostics 39.36 % |
| Corning Inc | Optical Communications 40.55 % |
| Johnson Controls International Plc | Americas 66.79 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Thermo Fisher Scientific Inc .
Thermo Fisher Scientific Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Thermo Fisher Scientific Inc | 251,761 | 370,688 | 55,912 |
| Taiwan Semiconductor Manufacturing Company Limited | 2,348,690 | 1,713,299 | 762,463 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Abbott Laboratories | 176,419 | 392,470 | 54,574 |
| Danaher Corporation | 160,859 | 418,450 | 66,733 |
| Intuitive Surgical Inc | 148,204 | 663,668 | 185,530 |
| PEERS TOTAL | 4,955,534 | 738,582 | 105,819 |
Sign in to see all peers for Thermo Fisher Scientific Inc .
Thermo Fisher Scientific Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Johnson and Johnson | United States 57.42 % |
| Abbott Laboratories | Non-US 61.62 % |
| Danaher Corporation | North America 39.49 % |
| Intuitive Surgical Inc | Geographic Distribution, Foreign 30.41 % |
| 3m Company | Americas 54.09 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Thermo Fisher Scientific Inc .
Thermo Fisher Scientific Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 20 companies in Thermo Fisher Scientific Inc's industry classification, broader than the peer set above. Market cap in millions of $.Thermo Fisher Scientific Inc ranks #1 of 20 companies by market capitalization in its industry, holding 38.32 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 3,051, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc | 251,761 | 38.32 % |
| 2 | Kla Corporation | 249,635 | 38.00 % |
| 3 | Coherent Corp | 55,187 | 8.40 % |
| 4 | Rockwell Automation Inc | 48,124 | 7.33 % |
| 5 | Onto Innovation Inc | 1,234 | 5.2% |
| 6 | Trimble Inc | 1,234 | 5.2% |
| 7 | Nova Ltd | 1,234 | 5.2% |
| 8 | Camtek Ltd | 1,234 | 5.2% |
| 9 | Mirion Technologies Inc | 1,234 | 5.2% |
| 10 | 908 Devices inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Thermo Fisher Scientific Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Thermo Fisher Scientific Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc | 251,761 | 46.48 % |
| 2 | Kla Corporation | 249,635 | 76.69 % |
| 3 | Coherent Corp | 1,234 | 12.3% |
| 4 | Rockwell Automation Inc | 1,234 | 12.3% |
| 5 | Onto Innovation Inc | 1,234 | 12.3% |
| 6 | Trimble Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Thermo Fisher Scientific Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Thermo Fisher Scientific Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Scientific & Technical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (31 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 44.10 % (avg) | - |
| Operating Margin | 17.58 % | industry median | +22.1 pp |
| EBITDA Margin | 22.83 % | 5.11 % (avg) | +17.7 pp |
| Capital Intensity (Capex / Revenue) | 3.66 % | 3.13 % (avg) | +0.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Thermo Fisher Scientific Inc's Valuation vs Competitive Position
Valuation multiples vs the Scientific & Technical Instruments industry average (31 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 26.6x | 54.1x | -27.5x |
| EV / EBITDA | 20.7x | 26.7x | -5.9x |
| P/B | 3.5x | 5.0x | -1.5x |
| Return on Equity | 13.37 % | industry aggregate | -4.30 % |
| Return on Invested Capital | 5.70 % | -1.73 % (avg) | 7.43 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Thermo Fisher Scientific Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 16.45 % | 4.86 % | 26.14 % | 21.71 % | 14.55 % | -4.58 % | 0.05 % | 3.91 % |
| Operating Margin | 15.53 % | 17.99 % | 24.19 % | 25.57 % | 18.69 % | 16.00 % | 17.11 % | 17.38 % |
| Return on Invested Capital | 4.95 % | 5.77 % | 8.90 % | 9.58 % | 7.05 % | 5.75 % | 5.81 % | 5.73 % |
| P/E | 32.5x | 34.7x | 30.1x | 32.2x | 31.2x | 32.8x | 32.7x | 33.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Thermo Fisher Scientific Inc's Strategic Group Map
Every company in Thermo Fisher Scientific Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Thermo Fisher Scientific Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Thermo Fisher Scientific Inc's BCG Growth-Share Matrix
Relative market share (vs Thermo Fisher Scientific Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Thermo Fisher Scientific Inc falls in the Cash Cow quadrant: relative market share of 1.01x vs its largest competitor, in an industry growing revenue 7.7% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Thermo Fisher Scientific Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 3,051 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 3.66 % vs industry average 3.13 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Thermo Fisher Scientific Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Thermo Fisher Scientific Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Thermo Fisher Scientific Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Thermo Fisher Scientific Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Thermo Fisher Scientific Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Market leader by capitalization in its industry (#1 of 20, 38.32 % share).
- Operating margin 22.1 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+3.5% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (26.6x vs 54.1x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
- Losing revenue share to the broader industry (-1.0 points over the past year).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Thermo Fisher Scientific Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Taiwan Semiconductor Manufacturing Company Limited | 1.82 | 2.51 | 0.02 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Danaher Corporation | - | 1.73 | 0.40 |
| Intuitive Surgical Inc | 1.43 | 4.80 | - |
Sign in to see all peers for Thermo Fisher Scientific Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Thermo Fisher Scientific Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Taiwan Semiconductor Manufacturing Company Limited | Q4 2025 | +37.6 % | +53.1 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Danaher Corporation | Q2 2026 | +5.5 % | +56.8 % |
| Intuitive Surgical Inc | Q2 2026 | +29.3 % | +23.9 % |
| PEERS TOTAL | +15.1 % | +67.9 % |
Sign in to see all peers for Thermo Fisher Scientific Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Thermo Fisher Scientific Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Taiwan Semiconductor Manufacturing Company Limited | Q4 2025 | +25.7 % | +39.1 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Danaher Corporation | Q2 2026 | +10.0 % | +8.5 % |
| Intuitive Surgical Inc | Q2 2026 | +13.4 % | -27.5 % |
Sign in to see all peers for Thermo Fisher Scientific Inc .
Thermo Fisher Scientific Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Taiwan Semiconductor Manufacturing Company Limited | 21.37% | 26.29% | 31.41% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Danaher Corporation | 4.72% | 5.44% | 7.66% |
| Intuitive Surgical Inc | 15.63% | 17.11% | 17.82% |
Sign in to see all peers for Thermo Fisher Scientific Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Thermo Fisher Scientific Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Thermo Fisher Scientific Inc | 36.52 | 5.43 |
| Taiwan Semiconductor Manufacturing Company Limited | 84.65 | 19.34 |
| Johnson and Johnson | 31.48 | 6.78 |
| Abbott Laboratories | 28.13 | 3.91 |
| Danaher Corporation | 40.45 | 6.41 |
| Intuitive Surgical Inc | 47.62 | 13.12 |
| PEERS AVERAGE | 22.92 | 3.29 |
Sign in to see all peers for Thermo Fisher Scientific Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.